Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China · Delayed Price · Currency is CNY 53.23
-0.71 (-1.32%)
At close: Feb 26, 2026
SHA:688193 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 164.42 | 175.91 | 162.76 | 293.94 | 286.13 | 247.23 |
Other Revenue | 1.44 | 1.44 | 1.65 | 9.91 | 6.18 | 2.67 |
| 165.86 | 177.35 | 164.41 | 303.85 | 292.31 | 249.9 | |
Revenue Growth (YoY) | -6.80% | 7.87% | -45.89% | 3.95% | 16.97% | 152.00% |
Cost of Revenue | 39.99 | 39.1 | 32.09 | 106.11 | 74.38 | 60.76 |
Gross Profit | 125.87 | 138.25 | 132.32 | 197.74 | 217.93 | 189.14 |
Selling, General & Admin | 113.84 | 119.98 | 118.1 | 155.04 | 127.4 | 102.3 |
Research & Development | 34.1 | 38.45 | 40.54 | 33.89 | 26.12 | 23.18 |
Other Operating Expenses | -0.61 | -2.03 | -0.69 | 0.86 | 0.83 | -4.6 |
Operating Expenses | 156.81 | 173.23 | 158.55 | 192.72 | 155.35 | 121.61 |
Operating Income | -30.94 | -34.98 | -26.23 | 5.02 | 62.58 | 67.53 |
Interest Expense | -0.3 | -0.29 | -0.43 | -0.36 | -0.26 | -0.09 |
Interest & Investment Income | 15.89 | 17.76 | 15.65 | 12.57 | 3.21 | 1.54 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0.12 | 0.56 | -0.2 | -0.28 |
Other Non Operating Income (Expenses) | -0.21 | -0.3 | -0.06 | 0.13 | -0.15 | 1.32 |
EBT Excluding Unusual Items | -15.57 | -17.83 | -11.19 | 17.93 | 65.18 | 70.02 |
Gain (Loss) on Sale of Investments | 0.35 | -0.24 | 0.66 | 0.98 | - | - |
Gain (Loss) on Sale of Assets | -0.25 | 0.14 | -0.05 | 0.14 | 0.76 | 0.51 |
Asset Writedown | -0.25 | -0.83 | -0.34 | -1.19 | -0.38 | -0.29 |
Other Unusual Items | 3.35 | 3.54 | 15.68 | 8.82 | 6.89 | - |
Pretax Income | -12.37 | -15.22 | 4.76 | 26.68 | 72.44 | 70.24 |
Income Tax Expense | -6.9 | -7.41 | -3.5 | 3.35 | 7.82 | 8.87 |
Net Income | -5.47 | -7.81 | 8.26 | 23.33 | 64.62 | 61.38 |
Net Income to Common | -5.47 | -7.81 | 8.26 | 23.33 | 64.62 | 61.38 |
Net Income Growth | - | - | -64.60% | -63.89% | 5.28% | 1541.45% |
Shares Outstanding (Basic) | 39 | 39 | 39 | 38 | 30 | 30 |
Shares Outstanding (Diluted) | 39 | 39 | 39 | 38 | 30 | 30 |
Shares Change (YoY) | 0.94% | -0.68% | 2.83% | 26.08% | 0.95% | 0.65% |
EPS (Basic) | -0.14 | -0.20 | 0.21 | 0.62 | 2.15 | 2.05 |
EPS (Diluted) | -0.14 | -0.20 | 0.21 | 0.61 | 2.13 | 2.04 |
EPS Growth | - | - | -65.57% | -71.36% | 4.41% | 1528.92% |
Free Cash Flow | 6.42 | 13.86 | -3.2 | -25.31 | 27.97 | 77.06 |
Free Cash Flow Per Share | 0.16 | 0.35 | -0.08 | -0.66 | 0.92 | 2.56 |
Dividend Per Share | 0.250 | 0.200 | 0.200 | 0.125 | - | - |
Dividend Growth | -16.67% | - | 60.00% | - | - | - |
Gross Margin | 75.89% | 77.95% | 80.48% | 65.08% | 74.56% | 75.69% |
Operating Margin | -18.66% | -19.73% | -15.95% | 1.65% | 21.41% | 27.02% |
Profit Margin | -3.30% | -4.41% | 5.02% | 7.68% | 22.11% | 24.56% |
Free Cash Flow Margin | 3.87% | 7.82% | -1.94% | -8.33% | 9.57% | 30.84% |
EBITDA | -15.83 | -20.86 | -13.43 | 17.42 | 70.93 | 73.32 |
EBITDA Margin | -9.54% | -11.76% | -8.17% | 5.73% | 24.27% | 29.34% |
D&A For EBITDA | 15.11 | 14.12 | 12.8 | 12.4 | 8.35 | 5.79 |
EBIT | -30.94 | -34.98 | -26.23 | 5.02 | 62.58 | 67.53 |
EBIT Margin | -18.66% | -19.73% | -15.95% | 1.65% | 21.41% | 27.02% |
Effective Tax Rate | - | - | - | 12.56% | 10.80% | 12.62% |
Revenue as Reported | 165.86 | 177.35 | 164.41 | 303.85 | 292.31 | 249.9 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.